scheduled between approximately 10:30 a.m. and 11:30 a.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before January 21, 1998, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Closed Committee Deliberations: On January 28, 1998, from 9:30 a.m. to 10 a.m., the meeting will be closed to permit discussion and review of trade secret and/or confidential information (5 U.S.C. 552b(c)(4)). FDA staff will present to the committee confidential information regarding present or future issues.

FDA regrets that it was unable to publish this notice 15 days prior to the January 28, 1998, Hematology and Pathology Devices Panel of the Medical Devices Advisory Committee meeting. Because the agency believes there is some urgency to bring this issue to public discussion and qualified members of the Hematology and Pathology Devices Panel of the Medical Devices Advisory Committee were available at this time, the Commissioner concluded that it was in the public interest to hold this meeting even if there was not sufficient time for the customary 15-day public notice.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: January 8, 1998.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 98–882 Filed 1–9–98; 2:15 pm]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting may be closed to the public.

Name of Committee: General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA regulatory issues.

Date and Time: The meeting will be held on January 29, 1998, 8:45 a.m. to 6 p.m., and January 30, 1998, 8:45 a.m. to 1:30 p.m.

Location: Gaithersburg Marriott Washingtonian Center, 9751 Washingtonian Blvd., Salons F and G, Gaithersburg, MD.

Contact Person: Gail G. Gantt, Center for Devices and Radiological Health (HFZ–410), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301–594–3090, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12519. Please call the Information Line or access the Internet address of http://www.fda.gov.cdrh for up-to-date information on this meeting.

Agenda: On January 29, 1998, the committee will discuss, make recommendations, and vote on one premarket approval application (PMA) for a wound dressing for use on diabetic foot ulcers and a second PMA for a wound dressing for use on venous stasis ulcers. On January 30, 1998, the committee will discuss, make recommendations, and vote on a PMA for a skin adhesive for wound edge approximation.

Procedure: On January 29, 1998 from 8:45 a.m. to 10 a.m and from 11 a.m. to 6 p.m., and on January 30, 1998, from 8:45 a.m. to 1:30 p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by January 22, 1998. Oral presentations from the public will be scheduled between approximately 8:45 a.m. and 9:45 a.m. on January 29 and 30, 1998. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before January 22, 1998, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Closed Presentation of Data: On January 29, 1998, from 10 a.m to 11 a.m. the meeting may be closed to permit discussion and review of trade secret and/or confidential information presented by the PMA sponsor(s) (5 U.S.C. 552b(c)(4)).

FDA regrets that it was unable to publish this notice 15 days prior to the January 29 and 30, 1998, General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee meeting. Because the agency believes there is some urgency to bring this issue to public discussion and qualified members of the General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee were available at this time, the Commissioner concluded that it was in the public interest to hold this meeting even if there was not sufficient time for the customary 15-day public notice.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C., app. 2).

Dated: January 8, 1998.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 98–887 Filed 1–9–98; 1:52 pm]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Vaccines and Related Biological Products Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

Name of Committee: Vaccines and Related Biological Products Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA regulatory issues.

Date and Time: The meeting will be held on January 30, 1998, 8 a.m. to 5 p.m.

Location: Holiday Inn, Versailles Ballrooms I and II, 8120 Wisconsin Ave., Bethesda, MD.

Contact Person: Nancy T. Cherry or Denise H. Royster, Center for Biologics Evaluation and Research (HFM–21), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301–827–0314, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12391. Please call the Information Line for up-to-date information on this meeting.

Agenda: The committee will discuss the influenza virus vaccine formulation for 1998 and 1999. The committee will

also hear short briefings on selected research programs in the Office of Vaccines Research and Review.

Procedure: On January 30, 1998, from 8 a.m. to 4 p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by January 21, 1998. Oral presentations from the public will be scheduled between approximately 8 a.m. to 9 a.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before January 21, 1998, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Closed Committee Deliberations: On January 30, 1998, from 4 p.m. to 5 p.m., the meeting will be closed to permit discussion where disclosure would constitute a clearly unwarranted invasion of personal privacy (5 U.S.C. 552b(c)(6)). The meeting will be closed to discuss personal information concerning individuals associated with the research programs.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: January 8, 1998.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 98–883 Filed 1–13–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Environmental Health Sciences; Submission for OMB Review; Comment Request; the Johnston County ADHD Study: Environmental, Reproductive, and Familial Risk Factors for Attention-Deficit/Hyperactivity Disorder

SUMMARY: Under the provisions of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the National Institute of Environmental Health Sciences (NIEHS), the National Institutes of Health (NIH) has submitted to the Office of Management and Budget (OMB) a request to review and approve the information collection listed below. This proposed information collection was previously published in the **Federal Register** on September 23, 1997, page 49697 and allowed 60-days for public comment. No public comments were received. The purpose of this notice is to allow an additional 30 days for public comment. The National Institutes of Health may not conduct or sponsor, and the respondent is not required to respond to, an information collection that has been extended, revised, or implemented on or after October 1, 1995, unless it displays a currently valid OMB control number.

PROPOSED COLLECTION: *Title:* The Johnston County ADHD Study: Environmental, Reproductive, and Familial Risk Factors for Attention-Deficit/Hyperactivity Disorder. *Type of Information Collection Request:* NEW. *Need and Use of Information Collection:* The primary goals of the study are to (1) estimate the prevalence of ADHD and it's subtypes in this community and how prevalence varies by demographic factors and (2) evaluate the effect of gestational age, birthweight and other pregnancy complications as risk factors for ADHD. Information will also be collected on childhood medical history, family history of ADHD, and mother's smoking, alcohol consumption and occupational exposures during pregnancy. Shed baby teeth will be collected to estimate cumulative lead burden and DNA will be collected from mothers, fathers, and children using cheek swabs to evaluate genes that might be important in ADHD. ADHD is one of the most frequent neuro-psychiatric conditions treated by child neurologists, psychologists, and pediatricians yet very little is known about its distribution in the community or its risk factors. This will be one of the first community-wide surveys of the prevalence and potential risk factors for ADHD. The findings will provide valuable information on (1) how much ADHD exists in this diverse county (2) how it varies by age, gender, and other demographic factors (3) what factors are associated with determining which children who have symptoms will get identified and/or treated and (4) risk factors for ADHD that might provide clues to prevention.

Frequency of Response: About 31 responses for teachers, 3.02 responses for mothers, 2.0 responses for fathers, 1 response for index children, 1 response for siblings. *Affected Public:* Johnston County Schools, Individuals or households; Businesses or other for-profit. *Type of Respondents:* Teachers, Parents, and children. The annual reporting burden is as follows: *Estimated Number of Annual Respondents:* 1138.3 *Estimated Number of Responses per Respondent:* see table below. *Average Burden Hours Per Response:* see table below. *Estimated Total Annual Burden Hours Requested:* 1,467.44. The annualized cost to respondents is estimated at: $31,192 for all respondents or $27.40 per respondent. There are no Capital Costs to report. There are no Operating or Maintenance Costs to report.

Type of respondents	Estimated number of respondents	Estimated number of responses per respondent	Average burden hours per response	Estimated total annual burden hours requested
Teachers	400	31	.18	2,204.4
Mothers	1,726	3.02	.36	1,897.97
Fathers	507	2.0	.17	169.34
Index child	507	1	.17	84.67
Siblings	275	1	.17	45.93
Total	3,415	7.604	.21	

Total Annual Burden: 4,402.31 ÷ 3 (years) = 1,467.44.

Request for Comments

Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) Whether the proposed collection of information is